Twilio Q2 Earnings Jump on Beat and Outlook Raise

Twilio Q2 earnings beat on Aug. 6, 2026, and management raised 2026 guidance, prompting renewed trading interest and heavier flows around the stock.

August 07, 2026·2 min read
View all news articles
Flat filled vector of a server with expanding circuits symbolizing Twilio Q2 earnings beat and outlook raise.

KEY TAKEAWAYS

  • Twilio reported Q2 revenue of $1.5 billion, up 22.0% reported and 17.0% organic year over year.
  • The quarter produced record non-GAAP income from operations of $285 million and free cash flow of $353 million.
  • Management raised full-year 2026 reported revenue-growth guidance to 18.0%-18.5% and organic growth to 13.0%-13.5%.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Twilio (TWLO) surprised investors on Aug. 6, 2026, by reporting stronger-than-expected second-quarter results and raising its full-year 2026 revenue outlook, citing accelerating organic growth, record profitability, and robust cash generation.

Q2 Results and Outlook

Twilio issued its second-quarter 2026 results in a press release on Aug. 6 at 4:05 p.m. ET, accompanied by an earnings presentation. The company reported revenue of $1.5 billion, up 22.0% on a reported basis and 17.0% organically year over year. Non-GAAP diluted earnings per share (EPS) were $1.47, while non-GAAP gross profit rose 18.0% to $736 million.

The quarter delivered record non-GAAP income from operations of $285 million and free cash flow of $353 million, highlighting stronger cash generation. GAAP diluted EPS was $6.68, which included a $5.91 per-share non-cash benefit from releasing a significant portion of the U.S. deferred-tax valuation allowance.

CEO Khozema Shipchandler said the quarter reflected organic growth acceleration, record profitability, and strong cash flow. He added, “We are in a powerful new chapter at Twilio, marked by another quarter of organic growth acceleration as well as record profitability and free cash flow.”

Twilio raised its full-year 2026 guidance for reported revenue growth to 18.0%–18.5%, up from 14.0%–15.0%, and for organic revenue growth to 13.0%–13.5%, up from 9.5%–10.5%. The company also increased its full-year non-GAAP income-from-operations and free cash flow guidance to $1.1 billion–$1.2 billion and projected third-quarter revenue of roughly $1.5 billion.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI employee arrested after a hidden device was discovered; company says models identified installer and found no data loss easing investor risk.

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital convertible notes proposal would raise $850 million and include a concurrent exchange, raising dilution concerns and pressuring shares.

Character.AI Bankruptcy Draws Disney Interest

Character.AI Bankruptcy Draws Disney Interest

Character.AI bankruptcy starts a Section 363 sale with Disney as stalking-horse and $20 million bid, compressing the auction and shaping recoveries.

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile downgrade after Piper Sandler cut its target, citing launch pace doubts and SpaceX competition, tightening trader positioning.

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia incident triggered precautionary coaster closures and state reviews, raising near-term operational risk to attendance and shares.

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 earnings raised guidance to a $101.2 billion sales midpoint while MedTech weakness may force traders to reprice device risk.